Ligand and Target Discovery by Fragment-Based Screening in Human Cells

  • Cell. 2017 Jan 26;168(3):527-541.e29. doi: 10.1016/j.cell.2016.12.029.
Christopher G Parker  1 Andrea Galmozzi  2 Yujia Wang  2 Bruno E Correia  3 Kenji Sasaki  2 Christopher M Joslyn  2 Arthur S Kim  2 Cullen L Cavallaro  4 R Michael Lawrence  4 Stephen R Johnson  4 Iñigo Narvaiza  5 Enrique Saez  6 Benjamin F Cravatt  7
Affiliations
  • 1. Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: [email protected].
  • 2. Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
  • 3. École Polytechnique Fédérale de Lausanne, 1015 Lausanne, Switzerland.
  • 4. Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08648, USA.
  • 5. The Salk Institute for Biological Studies, 10010 North Torrey Pines Road, La Jolla, CA 92037, USA.
  • 6. Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: [email protected].
  • 7. Department of Chemical Physiology, The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA. Electronic address: [email protected].
Abstract

Advances in the synthesis and screening of small-molecule libraries have accelerated the discovery of chemical probes for studying biological processes. Still, only a small fraction of the human proteome has chemical ligands. Here, we describe a platform that marries fragment-based ligand discovery with quantitative chemical proteomics to map thousands of reversible small molecule-protein interactions directly in human cells, many of which can be site-specifically determined. We show that fragment hits can be advanced to furnish selective ligands that affect the activity of proteins heretofore lacking chemical probes. We further combine fragment-based chemical proteomics with phenotypic screening to identify small molecules that promote adipocyte differentiation by engaging the poorly characterized membrane protein PGRMC2. Fragment-based screening in human cells thus provides an extensive proteome-wide map of protein ligandability and facilitates the coordinated discovery of bioactive small molecules and their molecular targets.

Keywords
FBLD; PGRMC2; adipogenesis; chemical probes; chemical proteomics; fragment-based ligand discovery; ligands; mass spectrometry; phenotypic screening; photoreactivity.
Products